| Ytd | 19.18% | |
| 1y | 61.25% |
| Open | 215.25 | Prev Close | 216.06 | Low | 209.67 | High | 215.76 | Mkt Cap | 30.97B |
| Vol | 1.10M | Avg Vol | 1.21M | EPS | 9.29 | P/E | 22.58 | Forward P/E | 12.62 |
| Beta | 0.18 | Short Ratio | 5.16 | Inst. Own | 96.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 195.16 | 200-d Avg | 177.27 | 1yr Est | 220.28 |
BIIB News
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier
BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, ap
Analyst raised sales estimates for Spinraza HD due to positive uptake. Biogen makes strides in key p
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend i
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States Distr
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clin
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it wi
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target f
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceutica
Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but repl
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as i
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and ra
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price t
Congresswoman Maria Elvira Salazar is buying stocks once again in 2026. Here's the new stocks sh
Biogen analyst upgraded to Buy, cites key growth drivers as Leqembi, Spinraza, Syfovre, and Empavell
Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst rating
Designation is supported by an exploratory analysis from the Phase 1b study showing that some childr
UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) today announced data, comprising two post
Data presentations across multiple kidney diseases illustrate the breadth of Biogen's nephrology
UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) today announced that The Lancet, a world-